Skip to main content
Menu
US

AlphaLISA Human & Mouse Ataxin 2 Detection Kit, 500 Assay Points

The AlphaLISA™ Human and Mouse Ataxin-2 Detection Kit is designed for the quantitative determination of Ataxin-2 in serum, buffered solution, or cell culture medium using a homogeneous (no wash steps, no separation steps) assay.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Feature Specification
Application Protein Quantification
Dynamic Range 20 - 20,000 pg/mL  
Limit of Detection 6.5 pg/mL  
Limit of Quantification 22 pg/mL  
Sample Volume 5 µL

The AlphaLISA™ Human and Mouse Ataxin-2 Detection Kit is designed for the quantitative determination of Ataxin-2 in serum, buffered solution, or cell culture medium using a homogeneous (no wash steps, no separation steps) assay.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Product Variants
Unit Size: 100 Assay Points
Part #:
AL3193HV
List Price
USD 1,094.00
Unit Size: 500 Assay Points
Part #:
AL3193C
List Price
USD 2,391.00
Unit Size: 5,000 Assay Points
Part #:
AL3193F
List Price
USD 15,950.00

Overview

Ataxin 2 is an RNA-binding protein encoded by the ATXN2 gene. Ataxin 2 accelerates ALS disease development in humans by causing neurodegeneration when carrying long polyglutamine tracts. TDP-43 modulates Ataxin 2 expression, according to recent studies in neurodegenerative conditions, and Ataxin 2 modifies TDP-43's toxicity in cellular and animal models. Future therapeutic endeavors should consider investigating both proteins together because new findings show that decreased Ataxin 2 levels inhibit TDP-43 aggregation.

Formats
  • Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
Features
  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Specifications

Application
Protein Quantification
Automation Compatible
Yes
Brand
AlphaLISA
Detection Modality
Alpha
Dynamic Range
20 - 20,000 pg/mL  
Limit of Detection
6.5 pg/mL  
Limit of Quantification
22 pg/mL  
Product Group
Kit
Sample Volume
5 µL
Shipping Conditions
Shipped in Blue Ice
Target
Ataxin-2
Target Class
Biomarkers
Target Species
Human
Mouse
Technology
Alpha
Therapeutic Area
Central Nervous System
Unit Size
500 Assay Points

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-1 of 1 Resources
Whitepaper Icon
Whitepaper
Shifting the treatment paradigm: the promise of gene therapy for neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s, are complex disorders that affect millions...

Scroll Icon